What is the recommended Targocid (Teicoplanin) dosing regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Targocid (Teicoplanin) Dosing Regimen

For adults with serious MRSA infections, administer teicoplanin with a loading dose of 6-12 mg/kg IV every 12 hours for 3 doses, followed by a maintenance dose of 6-12 mg/kg IV once daily, with higher doses (10-12 mg/kg) required for complicated infections such as endocarditis, osteomyelitis, and septic arthritis. 1

Adult Dosing by Indication

Standard Infections (Skin/Soft Tissue, Uncomplicated Bacteremia)

  • Loading regimen: 6-12 mg/kg IV every 12 hours for 3 doses 1
  • Maintenance: 6-12 mg/kg IV once daily 1
  • Duration: 7-14 days for skin/soft tissue infections; 2 weeks for uncomplicated bacteremia 1

Complicated/Severe Infections

Complicated Bacteremia:

  • Loading: 6-12 mg/kg IV every 12 hours for 3-6 doses 1
  • Maintenance: 6-12 mg/kg IV once daily 1
  • Duration: 4-6 weeks 1

Pneumonia:

  • Loading: 6-12 mg/kg IV every 12 hours for 3 doses 1
  • Maintenance: 6-12 mg/kg IV once daily 1
  • Duration: 7-21 days 1

Osteomyelitis/Septic Arthritis:

  • Loading: 6-12 mg/kg IV every 12 hours for 3 doses 1
  • Maintenance: 6-12 mg/kg IV once daily 1
  • Duration: >6 weeks for osteomyelitis; 3-4 weeks for septic arthritis 1
  • Note: Higher doses (12 mg/kg daily) are specifically recommended for septic arthritis 2

Endocarditis:

  • Loading: 6-12 mg/kg IV every 12 hours for 3 doses 1
  • Maintenance: 6-12 mg/kg IV once daily 1
  • Duration: 4-6 weeks for native valve; 6 weeks for prosthetic valve 1
  • Critical consideration: Monotherapy requires 12 mg/kg daily to achieve cure rates similar to vancomycin, with target trough levels >20 mg/L 2

Pediatric Dosing

  • Loading dose: 10 mg/kg IV every 12 hours for 3 doses 1
  • Maintenance: 6-10 mg/kg IV once daily 1
  • Maximum loading dose: 400 mg per dose 1

Loading Dose Rationale

A loading dose of 25-30 mg/kg (based on actual body weight) is warranted in critically ill patients to rapidly achieve therapeutic drug levels due to expanded extracellular volume from fluid resuscitation. 1 This principle applies to teicoplanin, which has a low volume of distribution similar to vancomycin 1. The standard 3-dose loading regimen (6-12 mg/kg every 12 hours) addresses the drug's slow accumulation to steady state, which would otherwise take 14 days 3.

Therapeutic Drug Monitoring

  • Target trough levels: 10-20 mg/L for most infections 3
  • Severe infections (endocarditis, osteomyelitis): Target trough >20 mg/L 2
  • Timing: Check trough before 4th or 5th dose 3
  • Note: Recent evidence suggests 600 mg daily (approximately 8-10 mg/kg for 60-75 kg adults) achieves therapeutic levels in 68% of patients versus 37% with 400 mg daily, without increased toxicity 4

Renal Dosing Adjustments

  • Loading dose: No adjustment required regardless of renal function 1
  • Maintenance dose: Reduce frequency based on creatinine clearance 5
  • Hemodialysis patients: 6 mg/kg every 12 hours for 3 loading doses, then maintenance every 72 hours 3
  • Negligible drug removal during hemodialysis 5

Common Pitfalls

Underdosing is the most common error with teicoplanin. Early trials using 200-400 mg daily showed poor results, particularly in endocarditis 2. The standard 6 mg/kg daily dose is inadequate for deep-seated staphylococcal infections when used as monotherapy 2. For complicated infections, do not hesitate to use 10-12 mg/kg daily or combination therapy with aminoglycosides 2.

Do not skip the loading regimen. Without loading doses, therapeutic concentrations are delayed due to the drug's 83-168 hour terminal half-life 3. The 3-dose loading regimen is essential for rapid therapeutic effect 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A critical review of the dosage of teicoplanin in Europe and the USA.

International journal of antimicrobial agents, 1994

Research

Clinical pharmacokinetics of teicoplanin.

Clinical pharmacokinetics, 2000

Research

Clinical pharmacokinetics of teicoplanin.

Clinical pharmacokinetics, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.